This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brooks, J. V.
Right arrow Articles by Orme, I. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brooks, J. V.
Right arrow Articles by Orme, I. M.

 Previous Article  |  Next Article 

Infection and Immunity, April 2001, p. 2714-2717, Vol. 69, No. 4
0019-9567/01/$04.00+0   DOI: 10.1128/IAI.69.4.2714-2717.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Boosting Vaccine for Tuberculosis

Jason V. Brooks,1,2 Anthony A. Frank,1,3 Marc A. Keen,1,2 John T. Bellisle,1,2 and Ian M. Orme1,2,*

Mycobacteria Research Laboratories1 and Departments of Microbiology2 and Pathology,3 Colorado State University, Fort Collins, Colorado 80523

Received 13 October 2000/Returned for modification 6 December 2000/Accepted 28 December 2000

An effective new vaccine for the control of tuberculosis is badly needed. While current research attempts to improve vaccination are concentrating on new prophylactic or immunotherapeutic vaccines, virtually no emphasis has been placed on boosting individuals already inoculated with Mycobacterium bovis BCG. It is shown here that mice vaccinated with BCG gradually lose their capacity to resist an aerosol challenge infection as they age. However, if these mice are inoculated with the 30-kDa mycolyl transferase A protein in midlife, after challenge when aged they express levels of protection in the lungs comparable to those of young mice, associated with minimal pathological damage.

* Corresponding author. Mailing address: Department of Microbiology, Colorado State University, Fort Collins, CO 80523. Phone: (970) 491-5777. Fax: (970) 491-5125. E-mail: iorme{at}lamar.colostate.edu.

Infection and Immunity, April 2001, p. 2714-2717, Vol. 69, No. 4
0019-9567/01/$04.00+0   DOI: 10.1128/IAI.69.4.2714-2717.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Radosevic, K., Wieland, C. W., Rodriguez, A., Weverling, G. J., Mintardjo, R., Gillissen, G., Vogels, R., Skeiky, Y. A. W., Hone, D. M., Sadoff, J. C., van der Poll, T., Havenga, M., Goudsmit, J. (2007). Protective Immune Responses to a Recombinant Adenovirus Type 35 Tuberculosis Vaccine in Two Mouse Strains: CD4 and CD8 T-Cell Epitope Mapping and Role of Gamma Interferon. Infect. Immun. 75: 4105-4115 [Abstract] [Full Text]  
  • Andersen, C. S., Dietrich, J., Agger, E. M., Lycke, N. Y., Lovgren, K., Andersen, P. (2007). The Combined CTA1-DD/ISCOMs Vector Is an Effective Intranasal Adjuvant for Boosting Prior Mycobacterium bovis BCG Immunity to Mycobacterium tuberculosis. Infect. Immun. 75: 408-416 [Abstract] [Full Text]  
  • Flaherty, D. K., Vesosky, B., Beamer, G. L., Stromberg, P., Turner, J. (2006). Exposure to Mycobacterium avium can modulate established immunity against Mycobacterium tuberculosis infection generated by Mycobacterium bovis BCG vaccination. J. Leukoc. Biol. 80: 1262-1271 [Abstract] [Full Text]  
  • Tsenova, L., Harbacheuski, R., Moreira, A. L., Ellison, E., Dalemans, W., Alderson, M. R., Mathema, B., Reed, S. G., Skeiky, Y. A. W., Kaplan, G. (2006). Evaluation of the Mtb72F Polyprotein Vaccine in a Rabbit Model of Tuberculous Meningitis. Infect. Immun. 74: 2392-2401 [Abstract] [Full Text]  
  • Horwitz, M. A., Harth, G., Dillon, B. J., Maslesa-Galic, S. (2005). Enhancing the Protective Efficacy of Mycobacterium bovis BCG Vaccination against Tuberculosis by Boosting with the Mycobacterium tuberculosis Major Secretory Protein. Infect. Immun. 73: 4676-4683 [Abstract] [Full Text]  
  • Martin, C. (2005). The dream of a vaccine against tuberculosis; new vaccines improving or replacing BCG?. Eur Respir J 26: 162-167 [Abstract] [Full Text]  
  • Mollenkopf, H. J., Grode, L., Mattow, J., Stein, M., Mann, P., Knapp, B., Ulmer, J., Kaufmann, S. H. E. (2004). Application of Mycobacterial Proteomics to Vaccine Design: Improved Protection by Mycobacterium bovis BCG Prime-Rv3407 DNA Boost Vaccination against Tuberculosis. Infect. Immun. 72: 6471-6479 [Abstract] [Full Text]  
  • Brandt, L., Skeiky, Y. A. W., Alderson, M. R., Lobet, Y., Dalemans, W., Turner, O. C., Basaraba, R. J., Izzo, A. A., Lasco, T. M., Chapman, P. L., Reed, S. G., Orme, I. M. (2004). The Protective Effect of the Mycobacterium bovis BCG Vaccine Is Increased by Coadministration with the Mycobacterium tuberculosis 72-Kilodalton Fusion Polyprotein Mtb72F in M. tuberculosis-Infected Guinea Pigs. Infect. Immun. 72: 6622-6632 [Abstract] [Full Text]  
  • Olsen, A. W., Williams, A., Okkels, L. M., Hatch, G., Andersen, P. (2004). Protective Effect of a Tuberculosis Subunit Vaccine Based on a Fusion of Antigen 85B and ESAT-6 in the Aerosol Guinea Pig Model. Infect. Immun. 72: 6148-6150 [Abstract] [Full Text]  
  • Goonetilleke, N. P., McShane, H., Hannan, C. M., Anderson, R. J., Brookes, R. H., Hill, A. V. S. (2003). Enhanced Immunogenicity and Protective Efficacy Against Mycobacterium tuberculosis of Bacille Calmette-Guerin Vaccine Using Mucosal Administration and Boosting with a Recombinant Modified Vaccinia Virus Ankara. J. Immunol. 171: 1602-1609 [Abstract] [Full Text]  
  • Pavelka, M. S. Jr., Chen, B., Kelley, C. L., Collins, F. M., Jacobs, W. R. Jr. (2003). Vaccine Efficacy of a Lysine Auxotroph of Mycobacterium tuberculosis. Infect. Immun. 71: 4190-4192 [Abstract] [Full Text]  
  • D'Souza, S., Rosseels, V., Romano, M., Tanghe, A., Denis, O., Jurion, F., Castiglione, N., Vanonckelen, A., Palfliet, K., Huygen, K. (2003). Mapping of Murine Th1 Helper T-Cell Epitopes of Mycolyl Transferases Ag85A, Ag85B, and Ag85C from Mycobacterium tuberculosis. Infect. Immun. 71: 483-493 [Abstract] [Full Text]  
  • Cheon, S.-H., Kampmann, B., Hise, A. G., Phillips, M., Song, H.-Y., Landen, K., Li, Q., Larkin, R., Ellner, J. J., Silver, R. F., Hoft, D. F., Wallis, R. S. (2002). Bactericidal Activity in Whole Blood as a Potential Surrogate Marker of Immunity after Vaccination against Tuberculosis. CVI 9: 901-907 [Abstract] [Full Text]  
  • Panigada, M., Sturniolo, T., Besozzi, G., Boccieri, M. G., Sinigaglia, F., Grassi, G. G., Grassi, F. (2002). Identification of a Promiscuous T-Cell Epitope in Mycobacterium tuberculosis Mce Proteins. Infect. Immun. 70: 79-85 [Abstract] [Full Text]  
  • Orme, I. M. (2001). The search for new vaccines against tuberculosis. J. Leukoc. Biol. 70: 1-10 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»